X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home News

A New UK Manufacturing Regulatory Framework On The Cards

Content Team by Content Team
30th January 2023
in News, Research & Development
A New UK Manufacturing Regulatory Framework On The Cards

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

As UK will introduce a customised framework for the innovative medicines’ regulation manufactured at the point where the care is received by the patient, it will be the first country to do so, as per the Medicine and Healthcare products Regulatory Agency- MHRA.

The manufacturing regulatory framework will apply across all point-of-care (POC) products manufactured across the UK once it is implemented, and shall include-

  • Advanced therapy medicinal products of the likes of gene therapy, tissue engineering products and cell therapy.
  • Printed products, especially the 3D ones
  • and Medicinal gases

This novel framework will make sure that there aren’t any regulatory barriers that obstruct innovative manufacturing and that the products that are manufactured through such routes stand by similar assurances to quality, security, and efficacy, just as what happens in the case of medicinal products that are conventional.

Medicines which happen to be new and are of very short shelf life as well as the ones which are customized can thus be made easily in the nearby ambulance or a hospital, thereby ensuring that the patients who are in their dire need can get them in no time. As per Health Minister Will Quince, this step is indeed a landmark initiative that will thwart unwanted regulatory barriers and thereby vacant hospital bed space while also ensuring to ease the pressure on health services.

Advantages that come with the new manufacturing regulatory framework

  • The professionals from the healthcare gamut will gain more access to a wider range of options as well as more effective treatment alternatives, which will also enhance their patients’ bonds with them.
  • Ward-off regulatory expectations, thereby allowing a product development which is much easier.

The new manufacturing regulatory framework happens to be based on public consultation, where views were sought about its introduction. The responses received put forth the fact that there was an urgent need for establishing a regulatory framework in order to come up with innovative medicinal products.

Execution of the new framework

There is a new legislation that is being developed which is going to make amendments to the Human Medicine and Clinical Trials legislation in the UK and will be tabled at the parliament later in 2023. The MHRA will also set out to start developing guidance that is in sync with the stakeholders’ aspirations so as to complement the new manufacturing regulatory framework that will be expected to be released in due course.

The MHRA point of care manufacturing lead Ian Rees stated that the guidance that will be accompanying the legislation is going to be pivotal for its execution as well as interpretation and the authorities involved shall ensure an engagement that is effective and will also have a dialogue with the stakeholders in order to make this promising framework a successful reality for the people in the UK.

Previous Post

With Discovery, Skullcap A Perfect Fit For Modern Medicine

Next Post

Monoclonal Antibodies Ideal Against Malaria- Suggests Study

Related Posts

WuXi Biologics and Virogen Bio partner to advance VG712
News

WuXi Biologics and Virogen Bio partner to advance VG712

19th June 2025
Construction of WuXi Biologics Microbial Manufacturing Site
News

Construction of WuXi Biologics Microbial Manufacturing Site

19th June 2025
Beyfortus From Sanofi to Make Imprint in 2025 26 RSV Season
News

Beyfortus From Sanofi to Make Imprint in 2025-26 RSV Season

19th June 2025
Thermo-Fischer-Accelerator Drug Development an Ideal Choice
News

Thermo Fischer Accelerator Drug Development an Ideal Choice

19th June 2025
IQVIA Custom Built AI Agents for Life Sciences Healthcare
News

IQVIA Custom-Built AI Agents for Life Sciences, Healthcare

19th June 2025
SCHOTT Pharma Invests
News

SCHOTT Pharma Invests EUR 100 Million in RTU Cartridges

9th June 2025
Next Post

Monoclonal Antibodies Ideal Against Malaria- Suggests Study

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In